| Literature DB >> 28933357 |
Eric S Donkor1, Jonathan A Osei2, Isaac Anim-Baidoo3, Samuel Darkwah4.
Abstract
Asymptomatic bacteriuria (ASB) is benign except in certain medical conditions such as pregnancy and immunosuppression. In Ghana, there are hardly any studies on urinary infections among sickle cell disease (SCD) patients, and the few studies carried out in Africa focused on pediatric SCD populations. The current study aimed to investigate the risk of ASB among SCD patients at a tertiary hospital in Ghana. This was a cross-sectional study involving 110 SCD patients and 110 age and sex matched healthy controls. Urine specimens were collected from all the study subjects and analyzed by standard microbiological methods. Demographic information were also collected from the study subjects. The overall ASB prevalence was significantly higher among SCD patients (17.2%) than among the control group (8.2%), and the relative risk was 2.11 (p = 0.0431; CI = 1.00-4.45). Being female was as a predictor of ASB among the SCD patients (OR = 14.76; CI = 11.23-18.29; p = 0.0103). The most common organism isolated from the study participants was coagulase negative Staphylococcus species (4.1%), followed by Escherichia coli (2.7%); etiology of ASB in the SCD patients was more diverse compared to healthy people. All the E. coli isolates were susceptible to amikacin, sparfloxacin and norfloxacin but resistant to ampicillin.Entities:
Keywords: Staphylococcus; bacteriuria; sickle cell disease; urine
Year: 2017 PMID: 28933357 PMCID: PMC5456336 DOI: 10.3390/diseases5010004
Source DB: PubMed Journal: Diseases ISSN: 2079-9721
Demographic features of the study participants.
| Variable | Sickle Cell Disease Group | Control Group | Significance |
|---|---|---|---|
| n (%) | n (%) | ||
| Gender | |||
| Male | 42 (38.1) | 42 (38.1) | |
| Female | 68 (61.9) | 68 (61.9) | |
| Mean age (years) | 26.0 (SD = 11.4) | 24.0 (SD = 12.0) | |
| Occupation | |||
| Unemployed | 56 (50.9) | 9 (8.2) | |
| Artisans | 40 (36.4) | 24 (21.8) | |
| Professionals | 14 (12.7) | 77 (70) | |
| Marital status | |||
| Married | 23 (20.9) | 26 (23.6) | |
| Single | 85 (77.2) | 82 (74.6) | |
| Widowed | 2 (1.9) | 2 (1.8) |
“n”—number or frequency.
ASB prevalence and causative organisms of SCD patients and healthy controls.
| Parameter | SCD Patients | Control Group | ||
|---|---|---|---|---|
| n | % | n | % | |
| Overall ASB prevalence | 19 | 17.3 | 9 | 8.2 |
| ASB prevalence in males | 1 | 2.4 | 1 | 2.4 |
| ASB prevalence in females | 18 | 26.5 | 8 | 11.8 |
| Causative organisms | ||||
| Coagulase negative | 4 | 3.6 | 5 | 4.5 |
| 4 | 3.6 | 2 | 1.8 | |
| 3 | 2.7 | 0 | 0 | |
| 3 | 2.7 | 1 | 0.9 | |
| 1 | 0.9 | 1 | 0.9 | |
| 1 | 0.9 | 0 | 0 | |
| 1 | 0.9 | 0 | 0 | |
| 1 | 0.9 | 0 | 0 | |
“n”—number or frequency; SCD—sickle cell disease; ASB—asymptomatic bacteriuria. Parameters showing statistical significance were: difference in overall ASB prevalence of SCD patients and control group (p = 0.043); difference in ASB prevalence of SCD male and female patients (p = 0.001).
Antibiogram of urinary bacterial isolates from SCD patients and healthy controls.
| ISOLATES | SOURCE | BA | CL | CH | PR | TE | CP | AK | AS | SC | OF | NX | LE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCD | S | S | R | S | S | S | S | R | S | S | S | S | |
| SCD | S | S | R | R | R | S | S | R | S | S | S | S | |
| SCD | R | S | S | S | R | S | S | R | S | S | S | S | |
| SCD | S | R | S | R | R | R | S | R | S | S | S | S | |
| NSCD | S | S | S | S | R | S | S | R | S | S | S | S | |
| NSCD | R | R | R | R | R | S | S | R | S | R | S | R | |
| CNS | NSCD | R | S | S | S | S | S | S | S | S | S | S | S |
| CNS | NSCD | R | R | R | S | S | S | S | R | S | S | S | S |
| CNS | NSCD | R | I | R | S | S | S | S | R | S | S | S | S |
| CNS | NSCD | S | R | R | S | R | S | S | R | S | S | S | S |
| CNS | NSCD | R | S | S | S | R | S | S | R | S | S | S | S |
| CNS | SCD | R | R | S | S | R | R | S | S | I | S | S | S |
| CNS | SCD | S | S | S | S | S | S | S | S | S | S | S | S |
| CNS | SCD | S | R | S | R | R | S | I | R | S | S | S | S |
| CNS | SCD | S | S | R | S | S | S | S | R | S | S | S | S |
| SCD | R | S | R | R | R | S | S | R | S | S | S | S | |
| NSCD | S | S | S | S | S | S | S | R | S | S | S | S | |
| SCD | S | S | S | S | S | S | S | R | S | S | S | S | |
| SCD | S | S | R | S | S | S | S | S | S | S | S | S | |
| SCD | S | S | R | R | R | S | S | R | S | S | S | S | |
| SCD | R | S | R | S | S | S | S | R | S | S | S | S | |
| SCD | R | R | S | R | R | S | R | R | S | S | S | S |
S. aureus—Staphylococcus aureus; K. oxytoca—Klebsiella oxytoca; CNS—coagulase-negative Staphylococcus sp.; E. coli—Escherichia coli; SCD—sickle cell disease; NSCD—non-sickle cell disease; R—resistant; S—susceptible; I—intermediate; BA—cotrimoxazole; AK—amikacin; CL—ceftizoxime; AS—ampicillin; CH—chloramphenicol; SC—sparfloxacin; PR—cephalexin; OF—ofloxacin; TE—tetracycline; NX—norfloxacin; CP—ciprofloxacin; LE—levofloxacin.